Next generation prophylactic human papillomavirus vaccines

Area of Science:

• Vaccinology and Virology
• Immunology
• Public Health

Background:

• Licensed bivalent and quadrivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccines are safe and effective prophylactic agents.
• Current HPV vaccines have limitations including high cost, type-specific protection, and lack of therapeutic activity.
• Transitioning to a two-dose vaccination schedule, particularly for adolescents, is becoming a global standard.

Purpose of the Study:

• To explore advancements in HPV vaccine technology addressing limitations of existing L1 VLP vaccines.
• To discuss the development of second-generation HPV vaccines with improved cost-effectiveness and broader applicability.
• To highlight novel approaches including alternative production systems, microbial vectors, and L2-based vaccines.

Main Methods:

• Review of current and emerging HPV vaccine technologies, including L1 VLP and L2-based prophylactic vaccines.
• Analysis of alternative production systems (e.g., E. coli, yeast) and novel delivery platforms (e.g., microbial vectors).
• Examination of evolving dosing strategies and their implications for vaccine efficacy and accessibility.

Main Results:

• Preliminary data suggest one dose of the bivalent HPV vaccine may offer prophylactic benefits.
• Second-generation L1 VLP vaccines are emerging, with Merck's nonavalent vaccine as the first market example.
• Development is underway for microbial vector-based vaccines and L2-based prophylactic vaccines.

Conclusions:

• Ongoing innovation in HPV vaccine development aims to reduce costs and expand protection.
• Decentralization of vaccine production is anticipated, potentially increasing availability in low-resource settings.
• Next-generation HPV vaccines hold promise for more accessible and comprehensive prevention and potential therapeutic strategies.